CHRAC17 Activators
CHRAC17 activators include a diverse array of chemical compounds that enhance the chromatin remodeling activity of CHRAC17 through distinct and interrelated biochemical pathways. Cyclic AMP (cAMP) and Forskolin elevate intracellular cAMP, which activates protein kinase A (PKA), leading to phosphorylation of substrates that may interact with CHRAC17, thus enhancing its chromatin remodeling activities. Concurrently, Phorbol 12-myristate 13-acetate (PMA) as a protein kinase C (PKC) activator, and Sphingosine-1-phosphate (S1P), through receptor-mediated signaling, may facilitate phosphorylation events that augment CHRAC17's role in modulating chromatin structure. Epigallocatechin gallate (EGCG) and Rolipram, by inhibiting competitive kinases and phosphodiesterase 4 respectively, potentially create a favorable environment for CHRAC17 activity through reduced competitive signaling and sustained cAMP levels.
The second paragraph must focus on histone modification compounds and their effects on CHRAC17 activity. Trichostatin A (TSA) and SAHA (Vorinostat) act as histone deacetylase inhibitors, leading to less compact chromatin, potentially improving CHRAC17's access and activity in chromatin remodeling. 5-Azacytidine's inhibition of DNA methyltransferases may facilitate CHRAC17 activity by inducing DNA hypomethylation and altering chromatin architecture. Nicotinamide inhibits sirtuin deacetylases, resulting in histone hyperacetylation, which could allow for more effective CHRAC17-mediated chromatin remodeling. Anacardic acid and MS-275 (Entinostat) further contribute to this regulation; Anacardic acid inhibits histone acetyltransferase enzymes, possibly affecting chromatin structure in a way that enhances CHRAC17 function, while MS-275 selectively inhibits Class I histone deacetylases, promoting chromatin states conducive to CHRAC17 activity. Collectively, these activators, by modulating the chromatin landscape, facilitate an environment that amplifies the chromatin remodeling capabilities of CHRAC17.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Cyclic AMP (cAMP) indirectly enhances the functional activity of CHRAC17 by activating protein kinase A (PKA), which can phosphorylate components of the CHRAC complex, potentially leading to increased chromatin remodeling activity of CHRAC17. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA functions as a PKC activator, which can phosphorylate various substrates, including those associated with chromatin remodeling complexes. This signaling action might enhance the activity of CHRAC17 by modifying its interaction with chromatin. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin enhances CHRAC17 activity by increasing intracellular cAMP levels, thereby activating PKA and influencing chromatin remodeling processes in which CHRAC17 is involved. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits several kinases, potentially reducing competitive signaling and allowing pathways involving CHRAC17 to be more active, which can enhance its chromatin remodeling function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4, thereby preventing the breakdown of cAMP. Elevated cAMP levels could enhance CHRAC17 function by activating PKA, which may phosphorylate substrates that interact with CHRAC17. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P through its receptor-mediated signaling can activate various kinases, which may lead to enhancement of CHRAC17 activity by influencing chromatin structure dynamics where CHRAC17 operates. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is an inhibitor of DNA methyltransferases, leading to hypomethylation of DNA and potentially enhancing the functional activity of CHRAC17 by altering chromatin structure. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $44.00 $66.00 $204.00 $831.00 | 6 | |
Nicotinamide acts as an inhibitor of sirtuin deacetylases. The resultant hyperacetylation of histones may enhance the functional activity of CHRAC17 by facilitating its role in chromatin remodeling. | ||||||
Anacardic Acid | 16611-84-0 | sc-202463 sc-202463A | 5 mg 25 mg | $102.00 $204.00 | 13 | |
Anacardic acid inhibits histone acetyltransferase enzymes, which could result in altered histone acetylation and indirectly enhance the chromatin remodeling activity of CHRAC17. | ||||||